| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 |
8-K: Other Events
As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determi... |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership |
| 27 Oct 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 |
| 10 Aug 2026 |
Form 4: Rottinghaus Scott T., Chief Medical Officer
Gave up 1,467 shares to cover exercise price or tax ($19.6K) |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ... |
| 02 Jul 2026 | 424B5 |
| 23 Jun 2026 |
8-K: Other Events
As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc... |
| 18 Jun 2026 |
8-K: Regulation FD Disclosure
Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research a... |
| 13 May 2026 | S-8 |
| 13 May 2026 | 10-Q |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 |
| 26 Mar 2026 | SCHEDULE 13G/A |
| 26 Mar 2026 |
8-K: Other Events
As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. s... |
| 13 Mar 2026 |
Form 4: Peterson Kristine, Director
Granted 20,000 Stock Option (right to buy) |
Loading...